 |
Also known as: Epogen, Procrit
The following information is NOT intended to endorse drugs or recommend therapy. While these reviews might be helpful, they are not a substitute for the expertise, skill, knowledge and judgement of healthcare practitioners in patient care.
Learn more about Epoetin alfa.
No reviews have yet been submitted. Be the first to review this drug.
Anemia more than triples a man's risk of death after suffering a stroke, a new study suggests. "Severe anemia among stroke survivors increases their chance of...
Dec 8, 2011 - Affymax, Inc. and Takeda Pharmaceutical Company Limited, today announced that the U.S. Food and Drug Administration (FDA) Oncologic Drugs...
Oct 24, 2011 - Affymax, Inc. today announced that the U.S. Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) will review the New...
Oct 10, 2011 - Affymax, Inc. (Nasdaq:AFFY) and Takeda Pharmaceuticals Global Research & Development Center, Inc., U.S., today announced data from multiple...
September 30, 2011 (Tokyo) - Chugai Pharmaceutical Co., Ltd. [Head Office: Chuo-ku, Tokyo; President: Osamu Nagayama (hereafter, Chugai)] announced today the...
Looking for answers? Ask a question or go join the epoetin alfa support group to connect with others who have similar interests.
Drugs.com provides accurate and independent information on more than 24,000 prescription drugs, over-the-counter medicines & natural products. This material is provided for educational purposes only and is not to be used for medical advice, diagnosis or treatment.
Data sources include Micromedex™ (updated Jan 27th, 2011), Cerner Multum™ (updated Jan 3rd, 2012), Wolters Kluwer™ (updated Jan 31st, 2012) and others.
To view content sources and attributions, refer to our editorial policy.
Copyright © 2000-2012 Drugs.com. All rights reserved.
We comply with the HONcode standard for trustworthy health information.
Verify here
